ABEO

MKT CAP:$308M

Abeona Therapeutics Inc.

Market Cap

$308M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$5.39+$0.08 (+1.48%)

Apr 24, 2026

Company Details

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III c...

CEO

Vishwas Seshadri

IPO Date

Sep 19, 1980

Website

www.abeonatherapeutics.com

Key Metrics TTM

Revenue

$6M

— YoY

Net Income

$71M

EPS (Diluted)

$1.01

Free Cash Flow

-$84M

Revenue / Share

$0.09

Gross Margin

26.3%

Operating Margin

-1536.9%

Net Margin

1223.1%

FCF Margin

-1448.5%

P/S

52.9x

P/E

4.3x

Earnings Reports

FY 2025

Mar 17, 2026

$6MEPS $1.01

Q4 2025

Mar 17, 2026

$5MEPS -$0.36

Q3 2025

Nov 12, 2025

$0EPS -$0.10

Q2 2025

Aug 14, 2025

$400.0KEPS $1.71

Q1 2025

May 15, 2025

$0EPS -$0.24

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 21	$0	$0	-$15M
Q4 21	$3M	-$10M	-$47M
Q1 22	$346.0K	-$10M	-$21M
Q2 22	$1M	-$6M	-$8M
Q1 23	$0	$0	-$12M
Q2 23	$4M	$2M	-$11M
Q3 23	$0	-$30.0K	-$11M
Q4 23	$0	-$721.0K	-$13M
Q1 24	$0	$0	-$14M
Q2 24	$0	$0	-$18M
Q3 24	$0	$0	-$15M
Q4 24	$0	-$776.0K	-$17M
Q1 25	$0	$0	-$20M
Q2 25	$400.0K	$300.0K	-$23M
Q3 25	$0	-$488.0K	-$24M
Q4 25	$5M	$2M	-$23M

Valuation

Quarter	P/S	P/E
Q3 21	38.6x	—
Q4 21	17.9x	—
Q1 22	12.6x	—
Q2 22	6.0x	—
Q1 23	11.7x	—
Q2 23	22.1x	—
Q3 23	23.0x	—
Q4 23	45.6x	—
Q1 24	88.3x	—
Q2 24	—	—
Q3 24	—	—
Q4 24	—	—
Q1 25	—	—
Q2 25	770.2x	5.4x
Q3 25	722.8x	3.5x
Q4 25	50.0x	4.1x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 21	-$10M	-$11M
Q4 21	-$30M	-$34M
Q1 22	-$14M	-$14M
Q2 22	-$9M	-$9M
Q1 23	-$12M	-$12M
Q2 23	-$10M	-$10M
Q3 23	-$6M	-$6M
Q4 23	-$9M	-$9M
Q1 24	-$15M	-$15M
Q2 24	-$13M	-$13M
Q3 24	-$12M	-$13M
Q4 24	-$17M	-$17M
Q1 25	-$18M	-$20M
Q2 25	-$19M	-$22M
Q3 25	-$21M	-$24M
Q4 25	-$18M	-$19M

Capital Expenditures

Quarter	CapEx
Q3 21	$402.0K
Q4 21	$3M
Q1 22	$103.0K
Q2 22	$0
Q1 23	$218.0K
Q2 23	$32.0K
Q3 23	$44.0K
Q4 23	$37.0K
Q1 24	$725.0K
Q2 24	$711.0K
Q3 24	$404.0K
Q4 24	$606.0K
Q1 25	$1M
Q2 25	$3M
Q3 25	$3M
Q4 25	$1M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 21	-100.0%	+12.3%
Q4 21	+0.0%	+184.1%
Q1 22	—	+43.4%
Q2 22	—	-34.3%
Q1 23	—	-19.1%
Q2 23	+16.7%	-71.7%
Q3 23	-100.0%	-45.9%
Q4 23	-100.0%	+46.6%
Q1 24	—	+19.0%
Q2 24	-100.0%	+27.1%
Q3 24	—	+35.4%
Q4 24	—	+26.2%
Q1 25	—	+37.7%
Q2 25	—	+29.8%
Q3 25	—	+56.5%
Q4 25	—	+69.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 21	$3M	—
Q4 21	$2M	66.7%
Q1 22	$862.0K	249.1%
Q2 22	$724.0K	72.4%
Q1 23	$770.0K	—
Q2 23	$927.0K	26.5%
Q3 23	$2M	—
Q4 23	$2M	—
Q1 24	$2M	—
Q2 24	$1M	—
Q3 24	$2M	—
Q4 24	$2M	—
Q1 25	$3M	—
Q2 25	$3M	707.5%
Q3 25	$3M	—
Q4 25	-$142.0K	-2.6%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q3 21	$9M	$6M	—
Q4 21	$13M	$4M	—
Q1 22	$12M	$4M	—
Q2 22	$7M	$3M	—
Q1 23	$8M	$4M	—
Q2 23	$9M	$5M	—
Q3 23	$7M	$4M	—
Q4 23	$7M	—	$5M
Q1 24	$7M	$7M	—
Q2 24	$9M	$9M	—
Q3 24	$9M	$6M	—
Q4 24	$9M	—	$7M
Q1 25	$10M	$10M	—
Q2 25	$6M	$17M	—
Q3 25	$4M	$19M	—
Q4 25	$7M	$10M	—

Revenue Segments

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$20M	$11M	$31M
Q2 22	$6M	$14M	$20M
Q3 22	$6M	$12M	$18M
Q4 22	$14M	$38M	$52M
Q1 23	$5M	$36M	$40M
Q2 23	$6M	$31M	$37M
Q3 23	$5M	$49M	$54M
Q4 23	$14M	$38M	$52M
Q1 24	$18M	$45M	$62M
Q2 24	$34M	$88M	$123M
Q3 24	$16M	$94M	$110M
Q4 24	$23M	$74M	$98M
Q1 25	$16M	$68M	$84M
Q2 25	$164M	$62M	$226M
Q3 25	$83M	$124M	$207M
Q4 25	$78M	$113M	$191M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 21	4M	+1.5%	+5.8%
Q4 21	4M	+6.7%	+12.7%
Q1 22	6M	+38.4%	+53.8%
Q2 22	6M	+0.2%	+50.2%
Q1 23	17M	+191.1%	+330.8%
Q2 23	18M	+6.6%	+330.2%
Q3 23	25M	+37.6%	+327.9%
Q4 23	26M	+3.1%	+340.2%
Q1 24	27M	+6.9%	+61.6%
Q2 24	51M	+87.5%	+184.3%
Q3 24	48M	-6.1%	+93.9%
Q4 24	41M	-14.6%	+60.6%
Q1 25	50M	+21.3%	+82.2%
Q2 25	67M	+33.9%	+30.1%
Q3 25	54M	-18.6%	+12.8%
Q4 25	66M	+21.9%	+61.1%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 21	$0	76
Q4 21	$33.3K	90
Q1 22	$3.8K	90
Q2 22	$11.1K	90
Q1 23	$0	57
Q2 23	$61.4K	57
Q3 23	$0	57
Q4 23	$0	84
Q1 24	$0	84
Q2 24	$0	84
Q3 24	$0	84
Q4 24	$0	136
Q1 25	$0	136
Q2 25	$2.9K	136
Q3 25	$0	136
Q4 25	$181	30K

Revenue / Employee